Navigation Links
Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
Date:5/21/2008

BERKELEY HEIGHTS, N.J., May 21 /PRNewswire-FirstCall/ -- Genta Incorporated (OTC Bulletin Board: GNTA) announced that multiple abstracts featuring its lead oncology products will be featured at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 30 - June 3, 2008.

The abstracts include the following:

-- Initial Phase 1 Clinical and Pharmacokinetic Assessment of G4544, an

oral gallium-containing Compound. Poster # 53C Abstract No: 8592

Saturday, May 31, 2008.

-- A Phase I/II Study to Determine the Feasibility and Efficacy of the

Triple Combination of Oblimersen (OBL), Abraxane (ABX), and

Temozolomide (TMZ) in Metastatic Melanoma and Normal LDH. Poster # 16

Abstract No: 9027 Sunday, June 1, 2008.

-- Effect of the Addition of Oblimersen (Bcl-2 antisense) to

Fludarabine/Cyclophosphamide for Relapsed/Refractory Chronic

Lymphocytic Leukemia (CLL) on Survival in Patients Who Achieve CR/nPR:

Five-year Follow-up from a Randomized Phase III Study. Abstract # 7008

Monday, June 2, 2008.

-- Prognostic Impact of Baseline LDH on Survival Independent of Tumor

Burden in Advanced Melanoma: Results of Phase III Trial of

Oblimersen-Dacarbazine (OBL-DTIC) vs. DTIC. (Publication).

-- Short IV Infusion of Oblimersen (OBL) in Patients with Solid Tumors:

Safety and Pharmacokinetics. (Publication).

-- Pharmacokinetics of Albumin-bound Paclitaxel (ABX) in combination with

Temozolomide (TMZ) and Oblimersen Sodium (OBL) in Patients with

Advanced Melanoma. (Publication).

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medici
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
2. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
3. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
4. Genta Incorporated Announces Third Quarter 2007 Financial Results
5. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
6. Genta Clinical Programs Featured at American Society of Hematology Meeting
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
10. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
11. Genta Receives Key Patent Related to Oral Gallium Compound G4544
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... (OFT) approval condition to the announced tender offer for all of ... As a result of the waiver, the transaction is no longer ... offer on January 24, 2014 following the currently scheduled expiration time, ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness ... Fitness Center by the Medical Fitness Association, a non-profit ... achieve their full potential. The Cadence Fitness & Health ... western suburbs and second in the Chicagoland area. ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... 2010 STAAR Surgical Company (Nasdaq: STAA ... invasive ophthalmic products, today reported results for the third ... grew 6% to $13.2 million reflecting core product (IOLs ... decrease in defocused product revenue as compared to the ...
... Nov. 2, 2010 Kensey Nash Corporation (Nasdaq: ... investor conferences in November.   Michael Celano, ... presentation, at the Oppenheimer 21st Annual Healthcare Conference at ... at 2:10 p.m. (ET).  To hear the live webcast ...
Cached Medicine Technology:STAAR Surgical Reports Continued Double Digit Core Revenue Growth 2STAAR Surgical Reports Continued Double Digit Core Revenue Growth 3STAAR Surgical Reports Continued Double Digit Core Revenue Growth 4STAAR Surgical Reports Continued Double Digit Core Revenue Growth 5STAAR Surgical Reports Continued Double Digit Core Revenue Growth 6STAAR Surgical Reports Continued Double Digit Core Revenue Growth 7STAAR Surgical Reports Continued Double Digit Core Revenue Growth 8STAAR Surgical Reports Continued Double Digit Core Revenue Growth 9STAAR Surgical Reports Continued Double Digit Core Revenue Growth 10STAAR Surgical Reports Continued Double Digit Core Revenue Growth 11STAAR Surgical Reports Continued Double Digit Core Revenue Growth 12STAAR Surgical Reports Continued Double Digit Core Revenue Growth 13STAAR Surgical Reports Continued Double Digit Core Revenue Growth 14STAAR Surgical Reports Continued Double Digit Core Revenue Growth 15STAAR Surgical Reports Continued Double Digit Core Revenue Growth 16STAAR Surgical Reports Continued Double Digit Core Revenue Growth 17
(Date:7/9/2014)... Cincinnati, OH, July 10, 2014 -- The World Health ... 60 minutes of moderate to vigorous physical activity (MVPA) ... most of their MVPA during school hours. Therefore, ... school hours would increase MVPA. In a new ... Pediatrics , researchers confirmed that time spent outdoors after ...
(Date:7/9/2014)... Researchers at the Perelman School of Medicine at ... Park Cancer Institute have received an $8 million grant ... effects of photodynamic light therapy (PDT) in patients with ... that most often manifests itself in the lining of ... to asbestos. The grant will fund a clinical trial ...
(Date:7/9/2014)... lung cancer, researchers have uncovered mutations in a cell-signaling ... new knowledge may expand treatments for patients because drugs ... or are in clinical trials. , Reporting July 9 ... Atlas (TCGA), including researchers at Washington University School of ... institutions, studied tumors from 230 patients with lung adenocarcinoma. ...
(Date:7/9/2014)... users in Russia might contribute to HIV transmission ... by researchers from Boston University Schools of Medicine ... Pavlov State University, sought to discover the effect ... a cohort of HIV-positive people with lifetime of ... by police were more likely to share needlesincreasing ...
(Date:7/9/2014)... 2014 There has been a sharp increase in ... Center using MyChart, the online, interactive service that allows ... their healthcare providers, schedule appointments, and renew prescriptions. , ... using MyChart each year increased five-fold, while ... than 10-fold, according to a study by Dr. ...
Breaking Medicine News(10 mins):Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3
... are being led to believe that, if they get ... it a ‘vaccine;’ but it is not a vaccine// ... under false pretenses. ,“The century-old circumcision ‘experiment’ ... sub-Saharan Africa be any different?” asks Dan Bollinger, director ...
... British Hindus and Sikhs to be allowed to hold open-air ... with a charity //fighting for the cause being allowed to ... of the Anglo Asian Friendship Society, has been given permission ... judge, Justice Andrew Collins. ,The development follows a ...
... in soil boosts happiness levels and could help restore healthy ... infection, says a study. ,British scientists led by ... the bacteria, named 'bacterium Mycobacterium vaccae', and found improvement in ... News. ,However, they said more work is needed ...
... testosterone, which plays a key role in health and ... ,People suffering with Alzheimer's lack the ability to ... As the disease progresses, individuals may also experience changes ... agitation, as well as delusions or hallucinations. ...
... Limited has achieved a significant milestone in its ... Drug Discovery Research (NDDR) team has finished the ... ,As per the recently signed multi-year ... Ranbaxy will further profile this drug candidate through ...
... end to the problems caused by obesity. Like magicians pulling rabbits ... another caused by failure to control one’s weight. // ,The ... small tubes - airways - that carry air in and out ... higher risk of developing asthma, US researchers have concluded after reviewing ...
Cached Medicine News:Health News:Promoting Circumcision to Prevent HIV is Misguided and Will Backfire: ICGI 2Health News:Obesity can Cause Asthma too 2
The Model 340DT is a new desk top pulse oximeter that was designed for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring....
The Model 305 is a hand-held, portable, lightweight oximeter designed for spot checking. It has a NiCad rechargeable battery....
... The Model 130 has expanded memory capabilities ... has memory to retain oxygen saturation and pulse ... modes to best suit your needs:, ,1. ... minutes of information for a single patient, making ...
... into comfortable holder, measuring switch is ... is performed., ,Large display of ... surroundings, back light automatically turns on ... compact contour and design provide steady, ...
Medicine Products: